ARS Pharmaceuticals, Inc.
SPRY
$9.72
-$0.08-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.08% | 68.51% | 114.71% | 20.32% | 15.94% |
| Total Depreciation and Amortization | 882.26% | 443.75% | 8.22% | -17.33% | 1.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 215.86% | 182.90% | 204.99% | -35.76% | -40.67% |
| Change in Net Operating Assets | -410.84% | -101.00% | 75.42% | 77.97% | 59.88% |
| Cash from Operations | -19.57% | 61.75% | 122.86% | 26.46% | 20.12% |
| Capital Expenditure | -700.00% | -778.46% | -221.71% | 56.63% | 80.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.87% | -526.89% | -21.30% | 119.36% | 37.17% |
| Cash from Investing | 82.50% | -532.25% | -21.70% | 119.14% | 37.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 59.68% | -40.34% | -56.28% | -38.85% | -20.80% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,025.76% | 1,148.13% | 949.41% | -98.35% | -98.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.10% | 49.33% | 85.56% | -189.94% | -210.70% |